A study analysing uncommon and insensitive mutations and their effect on prognosis in non-small cell lung cancer patients treated with EGFR-TKI
Latest Information Update: 22 Jun 2020
At a glance
- Drugs Gefitinib (Primary) ; Icotinib (Primary) ; Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacodynamics; Therapeutic Use
Most Recent Events
- 22 Jun 2020 New trial record
- 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology